TransCode Therapeutics, Inc. (RNAZ)
NASDAQ: RNAZ · Real-Time Price · USD
8.45
-0.07 (-0.82%)
Apr 28, 2026, 4:00 PM EDT - Market closed
TransCode Therapeutics Employees
TransCode Therapeutics had 12 employees as of December 31, 2025. The number of employees increased by 5 or 71.43% compared to the previous year.
Employees
12
Change (1Y)
5
Growth (1Y)
71.43%
Revenue / Employee
n/a
Profits / Employee
-$3,022,607
Market Cap
7.75M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| BioAtla | 41 |
| Processa Pharmaceuticals | 12 |
| MetaVia | 8 |
| Immuron | 7 |
| Indaptus Therapeutics | 5 |
| Acurx Pharmaceuticals | 4 |
| Silo Pharma | 3 |
| Addex Therapeutics | 2 |
RNAZ News
- 1 day ago - TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University - PRNewsWire
- 21 days ago - TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028 - PRNewsWire
- 2 months ago - TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients - PRNewsWire
- 2 months ago - TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development - PRNewsWire
- 2 months ago - TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138 - PRNewsWire
- 4 months ago - TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma - PRNewsWire
- 4 months ago - TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors - PRNewsWire
- 4 months ago - TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial - PRNewsWire